These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 3019845)
1. Peripheral neuropathy and ototoxicity of dichlorodiamineplatinum: instrumental evaluation. Preliminary results. Carenza L; Villani C; Framarino dei Malatesta ML; Porta RP; Millefiorini M; Antonini G; Bolasco P; Bandiera G; Marzetti L Gynecol Oncol; 1986 Oct; 25(2):244-9. PubMed ID: 3019845 [TBL] [Abstract][Full Text] [Related]
2. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cavaletti G; Bogliun G; Marzorati L; Zincone A; Marzola M; Colombo N; Tredici G Cancer; 1995 Mar; 75(5):1141-50. PubMed ID: 7850713 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233 [TBL] [Abstract][Full Text] [Related]
4. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195 [TBL] [Abstract][Full Text] [Related]
5. Early detection of cisplatin ototoxicity. Selected case reports. Fausti SA; Schechter MA; Rappaport BZ; Frey RH; Mass RE Cancer; 1984 Jan; 53(2):224-31. PubMed ID: 6537798 [TBL] [Abstract][Full Text] [Related]
10. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. van der Hulst RJ; Dreschler WA; Urbanus NA Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541 [TBL] [Abstract][Full Text] [Related]
11. Hearing loss--risk factor for cisplatin ototoxicity? Observations. Durrant JD; Rodgers G; Myers EN; Johnson JT Am J Otol; 1990 Sep; 11(5):375-7. PubMed ID: 2240186 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin neuropathy: clinical course and neurophysiological findings. LoMonaco M; Milone M; Batocchi AP; Padua L; Restuccia D; Tonali P J Neurol; 1992 Apr; 239(4):199-204. PubMed ID: 1317914 [TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer. Marin AC; Rierson B Ariz Med; 1979 Dec; 36(12):898-9. PubMed ID: 229809 [No Abstract] [Full Text] [Related]
14. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604 [TBL] [Abstract][Full Text] [Related]
16. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227 [TBL] [Abstract][Full Text] [Related]
17. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383 [TBL] [Abstract][Full Text] [Related]
18. [Peripheral neuropathies during treatment with cisplatin: clinical and electrophysiologic study of 11 cases]. Mabin D; Borsotti JP; Tea S; Le Mevel JC; Clavier J Rev Electroencephalogr Neurophysiol Clin; 1986 Feb; 15(4):341-8. PubMed ID: 3010401 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the hearing loss associated with cis-platinum treatment by high-frequency audiometry. Kujansuu E; Rahko T; Punnonen R; Karma P Gynecol Oncol; 1989 Jun; 33(3):321-2. PubMed ID: 2722056 [TBL] [Abstract][Full Text] [Related]